|
Market Closed -
Nasdaq
00:00:00 20/10/2026 +04
|
5-day change | 1st Jan Change | ||
| 447.09 USD | -0.59% |
|
-5.23% | -23.23% |
Company Valuation: Madrigal Pharmaceuticals, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 1,449 | 5,179 | 4,568 | 6,730 | 13,226 | 10,391 | - | - |
| Change | - | 257.45% | -11.79% | 47.33% | 96.52% | -21.43% | - | - |
| Enterprise Value (EV) 1 | 1,179 | 4,869 | 4,051 | 5,922 | 12,584 | 9,864 | 9,467 | 8,388 |
| Change | - | 313.04% | -16.81% | 46.21% | 112.48% | -21.61% | -4.03% | -11.39% |
| P/E | -5.79x | -16.8x | -11.6x | -14.1x | -45.3x | -71.4x | 85.9x | 21.4x |
| PBR | 7.15x | 26.6x | 11.3x | 9x | 22.1x | 22.9x | 12.9x | 6.38x |
| PEG | - | -0.9x | -0.7x | -1.48x | 1.1x | 1.4x | -0x | 0x |
| Capitalization / Revenue | - | - | - | 37.4x | 13.8x | 6.8x | 4.9x | 3.63x |
| EV / Revenue | - | - | - | 32.9x | 13.1x | 6.46x | 4.46x | 2.93x |
| EV / EBITDA | -4.87x | -16.6x | -10.7x | -11.9x | -42.1x | -55.5x | 79.2x | 14.4x |
| EV / EBIT | -4.86x | -16.6x | -10.6x | -11.9x | -41.9x | -53.1x | 59.6x | 12.6x |
| EV / FCF | -4.87x | -16.6x | -12.4x | -13x | -66.2x | -49.2x | 34.8x | 10.5x |
| FCF Yield | -20.6% | -6.01% | -8.04% | -7.72% | -1.51% | -2.03% | 2.87% | 9.55% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -14.63 | -17.23 | -19.99 | -21.9 | -12.85 | -6.258 | 5.204 | 20.89 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | 180.1 | 958.4 | 1,528 | 2,121 | 2,863 |
| EBITDA 1 | -242.1 | -293.1 | -380 | -496.8 | -298.6 | -177.7 | 119.5 | 582.2 |
| EBIT 1 | -242.5 | -293.6 | -380.5 | -497.9 | -300.1 | -185.8 | 158.7 | 663.3 |
| Net income 1 | -241.8 | -295.4 | -373.6 | -465.9 | -288.3 | -182 | 171.3 | 651.6 |
| Net Debt 1 | -269.9 | -309.5 | -517.5 | -807.7 | -642 | -526.9 | -924 | -2,002 |
| Reference price 2 | 84.74 | 290.25 | 231.38 | 308.57 | 582.34 | 447.09 | 447.09 | 447.09 |
| Nbr of stocks (in thousands) | 17,097 | 17,842 | 19,743 | 21,810 | 22,711 | 23,104 | - | - |
| Announcement Date | 24/02/22 | 23/02/23 | 28/02/24 | 26/02/25 | 19/02/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -71.9x | 6.45x | -55.69x | -.--% | 10.39B | |
| 18.77x | 6.69x | 13.41x | 1.58% | 65B | |
| 35.3x | 6.27x | 18.74x | 0.92% | 51.2B | |
| 27.56x | 7.53x | 23.83x | 0.05% | 51.19B | |
| 34.01x | 3.32x | 14.33x | -.--% | 43.93B | |
| 48.9x | 5.59x | 30.73x | -.--% | 41.96B | |
| -18.47x | 189.62x | -19.51x | -.--% | 38.14B | |
| 28.97x | 8.21x | 21.25x | 0.37% | 33.24B | |
| 29.19x | 6.17x | 16.01x | -.--% | 25.2B | |
| 30.74x | 5.69x | 19.09x | -.--% | 22.5B | |
| Average | 16.31x | 24.55x | 8.22x | 0.29% | 38.28B | |
| Weighted average by Cap. | 23.31x | 24.50x | 13.55x | 0.43% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- MDGL Stock
- Valuation Madrigal Pharmaceuticals, Inc.
Select your edition
All financial news and data tailored to specific country editions
